NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

Its product lineup is anchored by its oncology offerings, with drugs including Enhertu, Tagrisso, and Imfinzi as key ...

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

Other key accomplishments and milestones in 2024 include: Metastatic Pancreatic Ductal Adenocarcinoma Commenced enrollment ...